Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

Sunoco LP Announces Preferred Equity Offering

(NYSE:SUN) DALLAS, Sept. 4, 2025 /PRNewswire/ -- Sunoco LP (NYSE: SUN) ("Sunoco") today announced the launch of a private offering (this "offering") of 1,000,000 of its Series A Fixed-Rate Reset Cu...

What is the anticipated effect of this preferred equity issuance on Sunoco's common stock price and existing shareholder dilution? How will the proceeds from this private preferred equity offering be utilized and what is the expected impact on Sunoco's liquidity and growth initiatives? What are the pricing terms and conversion features of the Series A Preferred Units and how will they affect Sunoco's capital structure?
Symbol: SUN
Equity offering
9 days ago
Read more prnewswire

Sunoco LP Announces Private Offering of Senior Notes

(NYSE:SUN) DALLAS, Sept. 4, 2025 /PRNewswire/ -- Sunoco LP (NYSE: SUN) ("Sunoco") today announced a private offering (this "offering") of senior notes due 2031 in an aggregate principal amount of $...

What is the market demand and pricing for these notes relative to comparable issuances, and what does it imply about investor sentiment toward Sunoco's creditworthiness? How will the $1.7 billion debt issuance impact Sunoco's leverage ratio and its ability to fund dividends or share buybacks? What are the terms (coupon, maturity, covenants) of the 2031 and 2034 senior notes and how might they affect Sunoco's credit metrics?
Symbol: SUN
Financing
9 days ago
Read more prnewswire

BiomX CEO to Present at H.C. Wainwright 27th Annual Global Investment Conference

(BMXX) Presentation to Focus on Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) Presentation to Focus on Positive Topline Result...

Are there any regulatory or reimbursement challenges that could affect the timeline for BX211's onward development and market entry? What is the expected commercial potential and market size for a therapy treating diabetic foot osteomyelitis compared to existing treatments? How will the Phase 2 topline results for BX211 impact BMXX's revenue forecasts and valuation?
Symbol: BMXX
Clinical trials
9 days ago
Read more globenewswire